Abstract
While conducting exercise oncology experiments with anti-PD-1 (rat-derived; Bio-X-Cell, BE0146) in C57BL/6 mice with B16-F10 melanoma or EO771 breast tumours, we noted that results from isotype control (rat IgG2a; Bio-X-Cell, BE0089)-treated mice appeared to be substantially different from those in untreated mice from a prior study. This led us to postulate that the immunogenicity of the rat mAb was having unintended effects on the anti-tumour immune response. Hence, we investigated the levels of anti-rat antibodies in the plasma of untreated, IgG2a-treated and anti-PD-1-treated mice.